Marinomed Biotech (MARI) Stock Overview
A biopharmaceutical company, develops therapeutic products for indications in virology and immunology in Austria, other European countries, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
MARI Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Marinomed Biotech AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €19.00 |
| 52 Week High | €19.80 |
| 52 Week Low | €2.00 |
| Beta | -0.079 |
| 1 Month Change | 2.70% |
| 3 Month Change | 53.85% |
| 1 Year Change | 57.02% |
| 3 Year Change | -70.03% |
| 5 Year Change | -81.55% |
| Change since IPO | -75.00% |
Recent News & Updates
Recent updates
A Look At The Fair Value Of Marinomed Biotech AG (VIE:MARI)
May 25
Marinomed Biotech AG (VIE:MARI) Could Be Riskier Than It Looks
Feb 03Marinomed Biotech AG (VIE:MARI) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Apr 22Marinomed Biotech AG's (VIE:MARI) Analyst Just Slashed This Year's Estimates
Sep 22Shareholder Returns
| MARI | AT Pharmaceuticals | AT Market | |
|---|---|---|---|
| 7D | -2.3% | -0.03% | 1.2% |
| 1Y | 57.0% | -21.3% | 16.6% |
Return vs Industry: MARI exceeded the Austrian Pharmaceuticals industry which returned -21.3% over the past year.
Return vs Market: MARI exceeded the Austrian Market which returned 16.6% over the past year.
Price Volatility
| MARI volatility | |
|---|---|
| MARI Average Weekly Movement | 6.1% |
| Pharmaceuticals Industry Average Movement | 5.2% |
| Market Average Movement | 4.0% |
| 10% most volatile stocks in AT Market | 5.9% |
| 10% least volatile stocks in AT Market | 2.6% |
Stable Share Price: MARI's share price has been volatile over the past 3 months compared to the Austrian market.
Volatility Over Time: MARI's weekly volatility has decreased from 15% to 6% over the past year, but is still higher than 75% of Austrian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 39 | Andreas Grassauer | www.marinomed.com |
Marinomed Biotech AG, a biopharmaceutical company, develops therapeutic products for indications in virology and immunology in Austria, other European countries, and internationally. It operates through Virology, Immunology, and Other segments. The company’s products pipeline includes Budesolv for the treatment of allergic rhinitis; Tacrosolv, which is in Phase II clinical trial for inflammatory eye diseases; and Inhaleen for viral infection of the upper and lower respiratory tract.
Marinomed Biotech AG Fundamentals Summary
| MARI fundamental statistics | |
|---|---|
| Market cap | €33.79m |
| Earnings (TTM) | -€15.42m |
| Revenue (TTM) | €4.79m |
Is MARI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MARI income statement (TTM) | |
|---|---|
| Revenue | €4.79m |
| Cost of Revenue | €3.77m |
| Gross Profit | €1.03m |
| Other Expenses | €16.44m |
| Earnings | -€15.42m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
Sep 17, 2025
| Earnings per share (EPS) | -8.67 |
| Gross Margin | 21.40% |
| Net Profit Margin | -321.66% |
| Debt/Equity Ratio | -111.9% |
How did MARI perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/07/14 03:50 |
| End of Day Share Price | 2025/07/14 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Marinomed Biotech AG is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Vladimira Urbankova | Erste Group Bank AG |
| Alexander Rihane | First Berlin Equity Research GmbH |
| Matthias Greiffenberger | GBC AG |